A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Not Applicable

Not yet recruiting

• Conditions: Familial Pulmonary Fibrosis; Interstitial Lung Abnormalities; Interstitial Lung Diseases
• Interventions: Drug: Nerandomilast; Drug: Placebo

• Registration Number: NCT07201922
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis.

Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo.

Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months.

Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-30
• Study First Submitted QC: 2025-09-30
• Study First Posted: 2025-10-01
• Last Update Submitted: 2025-10-01
• Last Update Posted: 2025-10-02
• Study Start: 2026-01-23
• Primary Completion: 2029-05-14
• Study Completion: 2029-05-23

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Individuals ≥40 years of age at the time of first signed informed consent at Visit 1a
• Participants must have at least 1 first-degree relative (biological parent, sibling, or child) with confirmed pulmonary fibrosis (idiopathic pulmonary fibrosis [IPF], idiopathic nonspecific interstitial pneumonia [NSIP], and/or pulmonary fibrosis due to known genetic cause [e.g. short telomere syndrome, mucin 5B (MUC5B) mutation, surfactant protein mutations])
• High resolution computed tomography (HRCT) scan with evidence of interstitial lung abnormalities involving at least 5% of a single lung zone or interstitial lung disease (ILD), based on central evaluation
• Forced vital capacity (FVC) ≥80% of predicted normal at Visit 1b
• Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥70% of predicted normal at Visit 1b Further inclusion criteria apply.

Exclusion Criteria

• Prior known pulmonary fibrosis that, in the opinion of the Investigator, requires treatment with approved therapies
• Prebronchodilator forced expiratory volume in 1 second (FEV1)/FVC <0.7 at Visit 1b
• HRCT findings consistent with probable or definite usual interstitial pneumonia (UIP) pattern
• Any medical condition that is known to predispose to the development of pulmonary fibrosis (e.g. known connective tissue disease)
• Prior or current use of nerandomilast, nintedanib, or pirfenidone Further exclusion criteria apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nerandomilast	Nerandomilast	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Time to physiologic or radiologic worsening of ILA/ILD over the whole trial	up to 164 weeks	Defined as relative decline in forced vital capacity (FVC) % predicted of \>10% from baseline; or absolute decline in diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted \>10% from baseline; or absolute increase in weighted reticulovascular score (wRVS) \>2% and total disease extent (TDE) \>2.5% on chest high resolution CT scan (HRCT), as measured by e-Lung Quantitative HRCT scoring, from baseline

Secondary Outcome Measures

Name	Time	Method
Absolute change from baseline in wRVS on e-Lung Quantitative HRCT scoring at weeks 26, 52, and 104	at baseline, at weeks 26, 52 and 104
Absolute change from baseline in TDE on e-Lung Quantitative HRCT scoring at weeks 26, 52, and 104	at baseline, at weeks 26, 52 and 104
Time to absolute decline from baseline in FVC (% predicted) of >5% over 52 weeks and over the whole trial	up to 164 weeks
Time to absolute decline from baseline in DLCO (% predicted) of >10% over 52 weeks and over the whole trial	up to 164 weeks
Absolute change from baseline in FVC (% predicted) at weeks 26, 52, and 104	at baseline, at weeks 26, 52 and 104
Time to absolute increase in wRVS >2% and TDE >2.5% on chest HRCT, as measured by e-lung quantitative HRCT scoring over 52 weeks and over the whole trial	up to 164 weeks
Time to physiologic or radiologic worsening of ILA/ILD over 52 weeks	up to 52 weeks
Absolute change from baseline in DLCO (% predicted) at weeks 26, 52, and 104	at baseline, at weeks 26, 52 and 104
Time to relative decline from baseline in FVC (% predicted) of >10% over 52 weeks and over the whole trial	up to 164 weeks

Trial Locations

Locations (40)

University of California Los Angeles; 🇺🇸 Los Angeles, California, United States

University of Michigan Health System; 🇺🇸 Ann Arbor, Michigan, United States

HOP Louis Pradel; 🇫🇷 Bron, France

HOP Bichat; 🇫🇷 Paris, France

Hamamatsu University Hospital; 🇯🇵 Shizuoka, Hamamatsu, Japan

Royal Devon and Exeter Hospital, Wonford; 🇬🇧 Exeter, United Kingdom

Royal Brompton Hospital; 🇬🇧 London, United Kingdom

Clinical Research Specialists LLC; 🇺🇸 Kissimmee, Florida, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States

Brigham and Women's Hospital; 🇺🇸 Boston, Massachusetts, United States

Scroll for more (30 remaining)